Diabetic distal symmetric sensorimotor polyneuropathy (DSPN) is a chronic progressive disease affecting around one-third of the diabetic population and accounts for considerable morbidity, increased mortality, and reduced quality of life ([@B1],[@B2]). Recent long-term studies in type 2 diabetic patients indicate that the current strategies of intensive diabetes therapy or multifactorial cardiovascular risk intervention are not sufficient to slow the progression of DSPN ([@B3]--[@B5]). Thus, effective treatment of DSPN remains challenging for the physician ([@B1],[@B6]).

Based on the pathogenetic mechanisms of DSPN, potential disease-modifying therapeutic approaches have been developed including antioxidants such as α-lipoic acid (ALA) ([@B7]--[@B9]) to diminish increased oxidative stress ([@B10]). Other potential modalities include the aldose reductase inhibitors ([@B11]), growth factors ([@B12]), and the protein kinase C-β inhibitor ruboxistaurin ([@B13]). These drugs have been designed to favorably influence the underlying pathophysiology of the disorder rather than for symptomatic pain relief. However, several problems have been encountered previously in designing appropriate clinical trials in DSPN. Among these, the most important are as follows: *1*) the lack of homogeneity of patients studied with respect to both the form of neuropathy and the degree of glycemic control; *2*) different pathogenetic pathways, the relative importance of which may vary intraindividually; *3*) stages of neuropathy that are too advanced; *4*) the use of end points with rather large variability between individuals and between centers; *5*) the unknown relevance of end points used; and *6*) study durations too short to allow for a favorable functional or structural effect ([@B6],[@B14],[@B15]).

Treatment with ALA administered intravenously or orally for several weeks or months improves neuropathic symptoms and deficits ([@B7]--[@B9]). However, based on the assumption that a therapeutic agent may prevent worsening of DSPN but not cause improvement, clinical trials should be conducted for a minimum period of 3 years to achieve a clinically meaningful change of two Neuropathy Impairment Score (NIS) points ([@B16],[@B17]). Therefore, we assessed the efficacy and safety of oral treatment with 600 mg ALA once daily in mild-to-moderate DSPN.

RESEARCH DESIGN AND METHODS {#s5}
===========================

The Neurological Assessment of Thioctic Acid in Diabetic Neuropathy (NATHAN) 1 trial was a multicenter (36 centers in the U.S., Canada, and Europe \[[Supplementary Materials](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0503/-/DC1)\]), randomized, double-blind, placebo-controlled, two-arm, 1:1 allocation ratio, parallel-group clinical trial using film-coated tablets containing 600 mg ALA (Thioctacid HR; MEDA Pharma, Bad Homburg, Germany) that were administered once daily or matching placebo tablets with increased amounts of cellulose and lactose that were identical in appearance in diabetic patients with mild-to-moderate DSPN ([@B18]). The trial consisted of a 2-week screening phase, 6-week placebo run-in phase, 4-year double-blind phase, and 4-week washout phase. Approvals were obtained from the local ethics committees of all participating centers.

Inclusion criteria at the screening visit were age 18--64 years; type 1 or type 2 diabetes defined by the American Diabetes Association criteria (1997); diabetes duration ≥1 year; presence of stage 1 or 2a DSPN attributable to diabetes ([@B18]); stable insulin regimen, weight, diet, and physical activity level as judged by the investigator; NIS--Lower Limbs and seven nerve conduction tests (NIS-LL+7) score ≥97.5th percentile (corresponding to 4.43 transformed score points); NIS-LL ≥2 points; one of two abnormalities \[either *1*) abnormal nerve conduction attributes in two separate nerves ≥99th percentile for distal latency or ≤1st percentile for nerve conduction velocity or amplitude or *2*) abnormal heart rate during deep breathing (HRDB) ≤1st percentile or total symptom score (TSS) in the feet \<5 points\]; and being of the female sex and surgically sterilized, ≥1 year postmenopausal, or practicing an acceptable method of contraception.

Exclusion criteria were neuropathies other than DSPN; myopathy and other neurologic diseases that may might interfere with the assessment of the severity of DSPN; previous bilateral sural nerve biopsies; peripheral vascular disease with intermittent claudication; foot ulcers; high risk for visual loss; psychiatric, psychological, or behavioral symptoms that would interfere with the patient's ability to participate in the trial; active neoplastic disease except basal cell carcinoma; uncontrolled atrial fibrillation; clinically significant cardiac, pulmonary, gastrointestinal, hematologic, or other endocrine disease; organ transplants; aspartate aminotransferase or alanine aminotransferase \>2 times normal; serum creatinine \>1.8 and \>1.6 mg/dL for men and women, respectively; drug or alcohol abuse within the last year; use of investigational drug within the last 6 months; severe or anaphylactic reaction to multiple drugs, sulfur products, or biologic products; ketoacidosis or hypoglycemia within the last 3 months resulting in hospital admission; antioxidant therapy (\>400 IU vitamin E, \>200 mg vitamin C, or \>30 mg/day β carotene) or pentoxyphylline within the last month; γ-linolenic acid and ALA \>50 mg/day within the last 3 months; history of use of medications or vitamins known to cause peripheral neuropathy including but not limited to use of phenytoin or carbamazepine ≥15 years or use of \>100 mg/day pyridoxine within the last 12 months; and use of pain medications except for standard doses of salicylates, ibuprofen, indoles, fenamates, oxicams, or pyrazoles.

Outcomes {#s6}
--------

The primary outcome measure was a composite score including the NIS-LL+7 suggested by Dyck et al. ([@B16]) including *1*) vibration detection threshold, *2*) peroneal motor nerve conduction velocity (MNCV), *3*) peroneal motor nerve distal latency, *4*) peroneal compound muscle action potential (CMAP), *5*) tibial motor nerve distal latency, *6*) sural sensory nerve action potential amplitude, and *7*) change in HRDB. The primary criterion of efficacy in the confirmatory analysis was the absolute change in the NIS-LL+7 score expressed as normal deviates (nds from percentiles correcting for age and other applicable variables) between baseline (mean of visit during weeks 1 and 2 or last available value before randomization) and end point (mean of weeks 191 and 192 or last available value after randomization).

Secondary outcome measures included the NIS, NIS-LL, Neuropathy Symptoms and Change (NSC) score, TSS, cooling detection threshold, heat pain response slope (0.5--5.0), tibial nerve CMAP and MNCV, sural sensory nerve action potential latency, and sensory nerve conduction velocity (SNCV). In a response/progression analysis after 2 and 4 years, a clinically meaningful response was defined as a decrease in NIS or NIS-LL by ≥2 points, respectively, while clinically meaningful progression was defined as an increase in NIS or NIS-LL by ≥2 points, respectively ([@B16],[@B17]).

Duplicate measurements of these measures within 1 week were performed at baseline, after 2 years, and after 4 years, whereas single measurements were carried out at screening and after 6 months, 1 year, and 3 years except for the NIS and NSC, which were assessed as single assessments at screening and thereafter at 6-month intervals, and the TSS and foot inspection, assessed at 3-month intervals.

The NIS is the sum score of examinations of muscle weakness, reflex loss, touch pressure, vibration, joint position and motion, and pinprick of index finger and great toe and is scored for both sides of the body ([@B19]). The NSC scores (number, severity, and change) are derived from answers to 38 questions (muscle weakness, questions 1--19; sensation, questions 20--29; and autonomic symptoms, questions 30--38) ([@B7]). Experienced, trained, and certified (by P.J.D. and colleagues) physicians evaluated the NIS and NSC. Study physicians had participated in training sessions and actual examination of patients under observation using a formal certification process. The nerve conduction, quantitative sensory tests (QSTs), and autonomic tests were performed by trained and certified personnel (by P.A.L., W.J.L., P.J.D., and colleagues). All results were interactively evaluated by the Reading and Quality Assurance Centers (at Mayo Clinic and Health Partners). Eligibility, baseline conditions, wave forms, stimulus response patterns, and test values were also assessed.

Safety measures included monitoring of adverse events, vital signs, weight, 12-lead resting electrocardiogram, chest X-ray at baseline, concomitant medication, global assessment of tolerability, and physical examination. Laboratory tests including blood chemistry, hematology, blood glucose, and HbA~1c~ were performed at screening, baseline, and 2-month (1st year), 3-month (2nd year), and 6-month (3rd year) intervals.

Randomization {#s7}
-------------

Screened patients were assigned a unique five-digit number. Randomized patients were additionally assigned a four-digit randomization number at baseline. Patients were assigned to the two treatment groups according to a randomization list generated by the Biostatistics Department of MEDA Pharma. The random allocation was balanced using an undisclosed block size of six. The investigators and the monitor received sealed envelopes to enable decoding the individual blinded treatment in case of emergency.

Statistical analysis {#s8}
--------------------

### Confirmatory analysis. {#s9}

The following hypothesis was tested: H0:μT = μP vs. H1:μT≠μP, where μT and μP denote the mean change in NIS-LL+7 tests from baseline to end point in the ALA and placebo groups, respectively. A two-way ANOVA including the factors treatment and center was performed. Variances were allowed to differ between treatments. Degrees of freedom were derived according to Kenward-Rogers. A 95% CI for the treatment difference based on least squares (LS) estimates from the model without interactions was calculated. A second model including treatment and center interaction was fitted explanatorily.

### Interim analysis. {#s10}

An interim analysis was performed as soon as the 2-year data of most subjects were available. The complete table part of the study had been provided to and assessed by an independent supervisory committee. The decision on continuation of the study was based on the confirmatory test of the primary variable. At *P* \< 0.005, the study would have been stopped. To ensure a global type 1 error of 5%, the error level for the final analysis was set to α2 = 0.0452 according to the Šidák ([@B20]) inequality.

Depending on the structure of data, either contingency tables \[*n* (%)\] or descriptive statistics (*n*, mean, SD, median, range, quartiles) were presented for time courses and changes from baseline. Secondary end points were analyzed by applying a Wilcoxon Mann-Whitney test.

Adverse events were coded according to the World Health Organization-Adverse Reactions Terminology (ART). Global incidences on preferred term and body system class level were calculated based on different causality filters. Vital and laboratory variables were screened for notable individual and trend-like changes.

### Sample size calculation. {#s11}

We used a conservative approach to suggest that treatment with ALA may prevent worsening of DSPN but not necessarily cause improvement ([@B16]). A clinically meaningful treatment difference of 2.0 nds for the changes from baseline for NIS-LL+7 tests and statistical error probabilities α = 0.05 and β = 0.1 were assumed. Based on a two-sided *t* test, the following scenarios for SDs and sample size per group (*n*) were considered: SD 3.57, *n* = 68; SD 4, *n* = 86; SD 5, *n* = 133; SD 6, *n* = 191; SD 7, *n* = 211. To account for a relatively high dropout rate expected in this long-term study, randomization of 250 patients per arm was proposed. Analysis of the intention-to-treat population was primary for all efficacy variables. Homogeneity of baseline characteristics was investigated by exploratory statistical tests based on the intention-to-treat population on selected baseline variables.

RESULTS {#s12}
=======

Patient disposition, clinical characteristics, HbA~1c~, and vital signs {#s13}
-----------------------------------------------------------------------

The patient disposition throughout the trial according to the CONSORT Statement 2010 flow diagram ([@B21]) is shown in [Fig. 1](#F1){ref-type="fig"}. The demographic variables and outcome measures at baseline in both groups are shown in [Table 1](#T1){ref-type="table"}. As a sign of homogeneity, no significant differences among the groups were noted for any of the parameters listed except for HRDB (*P* = 0.0193).

![Patient disposition.](2054fig1){#F1}

###### 

Clinical characteristics of the intention-to-treat population at baseline

                                         ALA                Placebo            *P*
  -------------------------------------- ------------------ ------------------ --------
  *n*                                    230                224                
  Age (years)                            53.3 ± 8.3         53.9 ± 7.6         0.3607
  Sex (% male)                           66.1               67.0               0.8430
  BMI (kg/m^2^)                          29.7 ± 6.1         29.8 ± 6.1         0.9226
  Heart rate (bpm)                       76.3 ± 12.3        74.6 ± 12.6        0.1603
  Type 1/type 2 diabetes                 27.4 / 72.6        21.0 / 79.0        0.1111
  Diabetes duration (years)              13.3 (0.8--56.1)   13.5 (0.9--46.7)   0.4190
  Neuropathy duration (years)            3.0 (0.0--25.4)    3.2 (0.0--21.1)    0.2588
  Insulin treatment                      58.9               55.1               0.4170
  HbA~1c~                                8.9 ± 1.8          8.8 ± 1.9          0.6354
  Fasting blood glucose (mmol/L)         11.1 ± 4.68        10.9 ± 4.26        0.6529
  Nephropathy                            11.7               12.0               0.5935
  Retinopathy                            45.5               43.6               0.6833
  Neuropathy stage 1/stage 2a            11.3 / 88.7        9.8 / 90.2         0.6074
  NIS-LL+7 (nds)                         17.1 ± 8.4         16.8 ± 8.0         0.6740
  NIS (points)                           12.7 ± 8.6         12.2 ± 7.8         0.5062
  NIS-LL (points)                        9.8 ± 5.6          9.5 ± 5.3          0.6087
  Peroneal MNCV (m/s)                    38.5 ± 5.03        38.1 ± 6.48        0.4957
  Sural SNAP (µV)                        2.49 ± 3.38        2.43 ± 3.21        0.8387
  Vibration perception threshold (JND)   21.27 ± 3.18       21.21 ± 3.52       0.8393
  Cold detection threshold (JND)         17.86 ± 5.14       17.58 ± 5.33       0.5765
  Heart rate deep breathing (bpm)        7.26 ± 5.44        8.59 ± 6.59        0.0193
  NSC weakness (number)                  0.06 ± 0.30        0.03 ± 0.23        0.2353
  NSC weakness (severity)                0.10 ± 0.56        0.04 ± 0.31        0.1613
  TSS (points)                           2.4 ± 1.9          2.6 ± 1.8          0.2752

Data are means ± SD, median (range), or %. *P* values derived from χ^2^ test for binary data and from *t* tests otherwise. JND, just noticeable difference; SNAP, sensory nerve action potential.

Mean HbA~1c~ decreased from baseline by 0.67 ± 1.41% in the ALA group and by 0.48 ± 1.46% on placebo after 2 years. After 4 years, HbA~1c~ declined compared with baseline by 0.62 ± 1.59% with ALA and by 0.60 ± 1.78% during placebo without significant differences between the groups (*P* = 0.9313 after 4 years). After 4 years, systolic blood pressure decreased by 0.1 ± 16.1 mmHg in the ALA group and by 0.2 ± 16.5 mmHg in the group given placebo (*P* = 0.9770). The corresponding reductions in diastolic blood pressure were 3.5 ± 11.1 mmHg for ALA compared with 2.7 ± 9.8 for placebo (*P* = 0.5121). Heart rate declined by 2.6 ± 10.9 bpm with ALA treatment and by 2.1 ± 10.4 bpm in the placebo group after 4 years compared with baseline (*P* = 0.7115). Weight increased slightly by 1.3 ± 5.4 kg in the ALA-treated group compared with 0.9 ± 8.6 in the placebo group (*P* = 0.6157).

The changes in the clinical neuropathy scores and nerve function tests from baseline to 2 and 4 years are summarized in [Table 2](#T2){ref-type="table"}. The NIS-LL+7 composite score decreased after 4 years compared with baseline on ALA (LS mean −0.45) and increased on placebo (LS mean +0.34) without reaching statistical significance between the groups (ALA-placebo difference in LS means 0.78 \[95% CI −0.16 to 1.73\]; *P* = 0.105). After 4 years, NIS improved significantly on ALA and worsened on placebo (*P* = 0.028) while the differences from baseline between the groups reached borderline significance for the pinprick test of NIS (*P* = 0.074) and NIS-LL (*P* = 0.0505). The muscular weakness subscore of NIS-LL improved significantly on ALA and deteriorated on placebo (*P* = 0.045). No significant differences between the groups after 4 years were noted for the NIS-LL subscores sensory function and reflexes. Response analysis after 4 years revealed that the percentages of clinical responders (decrease in NIS or NIS-LL by ≥2 points) were higher while at the same time those of progressors (increase in NIS or NIS-LL by ≥2 points) were lower on ALA compared with placebo. This difference was statistically significant for both NIS (*P* = 0.013) and NIS-LL (*P* = 0.025). The NSC scores for weakness number and severity, respectively, improved on ALA and worsened on placebo (*P* = 0.005 and *P* = 0.008). No significant differences between both groups after 4 years were noted for the nerve conduction parameters, QST, HRDB, or TSS.

###### 

Changes in clinical neuropathy scores and nerve function tests from baseline to 2 and 4 years

                                     2 Years        4 Years                                                       
  ---------------------------------- -------------- -------------- ---------------------------------------------- --------------
  *n*                                214            207            215                                            207
  Composite score                                                                                                 
   NIS-LL+7 (nds)                    −0.40 ± 4.92   0.19 ± 4.74    −0.37 ± 5.59[\*](#t2n1){ref-type="table-fn"}   0.29 ± 5.37
  NIS and subscores                                                                                               
   NIS                               −0.54 ± 6.62   0.12 ± 6.13    −0.68 ± 6.44[†](#t2n2){ref-type="table-fn"}    0.61 ± 6.61
   NIS pinprick                      −0.06 ± 1.48   −0.05 ± 1.44   −0.07 ± 1.60[‡](#t2n3){ref-type="table-fn"}    0.05 ± 1.43
   NIS-LL                            −0.38 ± 4.52   0.03 ± 4.22    −0.34 ± 4.48[§](#t2n4){ref-type="table-fn"}    0.43 ± 4.49
   NIS-LL sensory function           −0.34 ± 3.02   −0.09 ± 2.92   −0.12 ± 3.01                                   0.10 ± 2.89
   NIS-LL muscular weakness          −0.15 ± 1.66   0.05 ± 1.85    −0.21 ± 1.57[†](#t2n2){ref-type="table-fn"}    0.17 ± 2.12
   NIS-LL reflexes                   0.10 ± 1.63    0.07 ± 1.57    0.03 ± 1.75                                    0.16 ± 1.80
   NIS responders                    37.9           35.2           41.1[†](#t2n2){ref-type="table-fn"}            30.0
   NIS unchanged                     35.6           32.4           29.7[†](#t2n2){ref-type="table-fn"}            31.9
   NIS progressors                   26.5           32.4           29.2[†](#t2n2){ref-type="table-fn"}            38.1
   NIS-LL responders                 34.7           34.8           35.6[†](#t2n2){ref-type="table-fn"}            29.0
   NIS-LL unchanged                  42.0           35.2           40.2[†](#t2n2){ref-type="table-fn"}            36.2
   NIS-LL progressors                23.3           30.0           24.2[†](#t2n2){ref-type="table-fn"}            34.8
  Nerve function tests                                                                                            
   Peroneal MNCV (m/s)               0.04 ± 3.89    0.18 ± 3.99    −0.35 ± 4.23                                   −0.06 ± 4.07
   Sural SNAP (µV)                   −0.00 ± 2.17   −0.07 ± 1.96   −0.20 ± 2.34                                   −0.15 ± 2.43
   Foot VPT (JND)                    0.47 ± 2.12    0.58 ± 2.11    0.87 ± 2.35                                    0.76 ± 2.38
   Cold detection threshold (JND)    0.65 ± 3.56    0.87 ± 3.33    1.12 ± 3.96                                    1.28 ± 3.43
   Heart rate deep breathing (bpm)   −0.68 ± 3.39   −1.06 ± 3.23   −0.67 ± 4.44[¶](#t2n5){ref-type="table-fn"}    −1.35 ± 3.72
  Neuropathic symptoms                                                                                            
   NSC weakness (number)             −0.02 ± 0.30   0.04 ± 0.42    −0.04 ± 0.26[†](#t2n2){ref-type="table-fn"}    0.04 ± 0.42
   NSC weakness (severity)           −0.03 ± 0.40   0.03 ± 0.48    −0.05 ± 0.39[†](#t2n2){ref-type="table-fn"}    0.04 ± 0.50
   TSS                               −0.27 ± 2.46   −0.04 ± 2.16   −0.22 ± 2.42                                   −0.21 ± 2.45

Data are means ± SD or %. All *P* values calculated vs. placebo, with two-way ANOVA for NIS-LL+7 and Wilcoxon Mann-Whitney tests otherwise. JND, just noticeable difference; SNAP, sensory nerve action potential; VPT, vibration perception threshold.

\**P* = 0.105.

†*P* \< 0.05.

‡*P* = 0.074.

§*P* = 0.0505.

¶*P* = 0.087.

Safety analysis {#s14}
---------------

The incidences of treatment-emergent adverse events (TEAEs) were 214 (92.6%) on ALA and 203 (90.2%) on placebo, respectively. Two (0.9%) patients on ALA and one (0.7%) patient on placebo discontinued study treatment as a result of lack of tolerability (i.e., because of an adverse event with "likely" causal relationship to study medication as judged by the investigator). Analysis of TEAEs by the body system class showed that heart rate, rhythm disorders, and myocardial, endocardial, pericardial, valvular, and urinary system disorders tended to be more frequent on ALA than on placebo ([Supplementary Table 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0503/-/DC1)). No significant differences in the incidences of the individual cardiovascular disorders were observed between the groups ([Supplementary Table 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0503/-/DC1)). Corrected QT interval (QTc) prolongation \>60 ms was significantly more frequent on placebo than that on ALA (10 \[5.0%\] vs. 3 \[1.4%\]; *P* = 0.0497). Global assessment of treatment tolerability by investigators and patients showed no differences between the groups ([Supplementary Table 3](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc11-0503/-/DC1)).

Serious adverse events (SAEs) occurred in 88 (38.1%) patients in the ALA group and in 63 (28.0%) of those receiving placebo. The incidence of SAEs in the ALA group versus that in the placebo group was 31 (13.4%) vs. 20 (8.9%), respectively, (*P* = 0.125) for cardiovascular disorders; 5 (2.2%) vs. 7 (3.1%) (*P* = 0.528) for cerebrovascular disorders; 20 (8.7%) vs. 13 (5.7%) (*P* = 0.235) for infections; 23 (10.0%) vs. 14 (6.2%) for inflicted injuries (including surgical interventions, coronary angiography or angioplasty, and fractures; *P* = 0.144); and 3 (1.3%) vs. 6 (2.7%) (*P* = 0.294) for deaths.

CONCLUSIONS {#s15}
===========

The results of this longest randomized clinical trial ever conducted in DSPN demonstrate that 4-year treatment with the antioxidant ALA did not influence a composite score consisting of the NIS-LL+7 but improved neuropathic impairments scored by the NIS and NIS-LL, particularly small fiber and muscular function. The lack of improvement in the composite score was predominantly due to the fact that nerve conduction deficits in the placebo-treated group did not progress. Thus, secondary prevention of progression of the composite end point by treatment with ALA was not readily achievable. In contrast, a response analysis of clinically meaningful improvement and progression in these scores by at least two points ([@B16],[@B17]) revealed that the percentages of NIS and NIS-LL responders with mild-to-moderate DSPN were significantly higher on ALA, whereas the progressors were more frequent with placebo. To achieve these favorable effects, 4 years of treatment using 600 mg ALA once daily were necessary. Safety analysis showed that SAEs were slightly more frequent in patients receiving ALA, but more deaths occurred in the placebo group.

Similar to recent multicenter trials in DSPN ([@B22]), only a minor progression of the various measures of DSPN was observed in the placebo group over 4 years in the present trial. Therefore, improvement rather than slowing of progression was required for most outcomes to demonstrate efficacy. Because nerve conduction attributes did not deteriorate in the placebo group and did not improve with ALA, the composite primary end point could not be expected to ameliorate despite the improvement in neuropathic deficits. One reason for the lack of deterioration of nerve conduction attributes during placebo treatment could be the reduction in mean HbA~1c~ by 0.6% in this group. However, the calculation of the sample size and trial duration was based on the assumption that a treatment effect slows the progression of DSPN without improving it ([@B16]). This concept has been challenged by recent findings, suggesting that DSPN progresses very slowly or may even improve in placebo-treated patients participating in randomized clinical trials ([@B11],[@B13],[@B22]). A progressive improvement in neuropathic symptoms over 1 year was observed in placebo-administered patients with mild symptomatic DSPN ([@B22]). In a recent multicenter study, patients with mild-to-moderate DSPN randomized to placebo showed an improvement of 2.0 ± 8.0 m/s in summed median and sural SNCV after 1 year, which was associated with improvements in glycemic control and serum triglyceride levels ([@B23]). Dyck et al. ([@B15]) assessed clinimetric performance of DSPN end points in single and multicenter trials. They concluded that the main reasons why it is difficult to demonstrate monotonic worsening of neuropathic end points appears to be a very slow worsening of DSPN, improvement of symptoms and signs in the placebo group, and measurement noise. Demonstrating disease progression in DSPN trials may be more likely when *1*) patients with developing rather than established DSPN are selected, *2*) type 1 diabetic patients are preferentially recruited, *3*) patients are selected who cannot achieve ideal glycemic control, *4*) end points chosen are known to show monotonic worsening, and *5*) a restricted number of centers and expert examiners are used.

The reasons for the disparity between the effects of ALA on neuropathic deficits and nerve conduction or QST are not understood, but the same pattern was observed in the short-term Symptomatic Diabetic Neuropathy (SYDNEY) trial over 3 weeks ([@B7]). The mechanisms of the improvement in neuropathic impairments may be related to an improvement in nerve blood flow mediated by the antioxidant action of the drug. In the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study, oral administration of 300 mg ALA per day to patients with the metabolic syndrome resulted in a significant increase in endothelium-dependent brachial artery flow--mediated vasodilation and reductions in plasma levels of interleukin-6 and plasminogen activator-1 compared with placebo after 4 weeks, suggesting that the drug may improve endothelial dysfunction via anti-inflammatory and antithrombotic mechanisms ([@B23]). Interestingly, prevention of endothelial dysfunction via activation of AMP-activated protein kinase by ALA was postulated as a possible mechanism to explain the weight loss achieved after 20 weeks of ALA treatment in obese Korean subjects ([@B24]).

There is no firm explanation for the higher incidence of SAEs on ALA than placebo, given that only two patients on ALA and one patient on placebo discontinued study treatment due to adverse events with "likely" causal relationship to study medication as judged by the investigator. Moreover, when SAEs due to cardiovascular/cerebrovascular disorders/procedures and deaths were summarized, 34 (14.7%) patients on ALA and 27 (12.0%) patients on placebo were affected (*P* = 0.394). On the other hand, QTc prolongation \>60 ms was significantly more frequent on placebo than on ALA (5.0 vs. 1.4%; *P* = 0.0497) and more deaths were observed with placebo than with ALA (3 \[1.3%\] vs. 6 \[2.7%\]). Thioctacid is an over-the-counter drug that has been widely prescribed in Germany for decades, and postmarketing surveillance data sources from Germany showed low rates of adverse drug reactions comparable with those reported in previous clinical trials ([@B25]).

In conclusion, 4-year treatment with ALA in mild-to-moderate DSPN was well tolerated and was associated with improvement of neuropathic impairments but not nerve conduction attributes. Therefore, the primary composite end point did not change significantly. The clinical progression of DSPN in the placebo group within the setting of this randomized clinical trial with good retention of patients throughout a 4-year period was relatively slow. Hence, prediction of a treatment effect aimed at halting the progression of DSPN based on epidemiologic data indicating significant progression may not be appropriate. The designs of future trials in similar diabetic populations should anticipate a long-term stable neuropathic condition. For demonstration of efficacy, the drug or combinations of drugs that impact the different nerve fibers affected in DSPN that are tested in the future must achieve a clinically relevant neurologic improvement.
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